Recruitment unclearEUCTR 2016-000118-31
A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2)
This historical record does not confirm current site availability.
Historical research recordUnited KingdomSchizophrenia
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- United Kingdom
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
- Sponsor type
- University
- Study type
- Biological
- Intervention type
- Biological
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2016-000118-31
- Official title
Show the full official title
A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2)
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
United Kingdom
Registry details
Historical country statuses
- United Kingdom — GB - no longer in EU/EEA
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, a university.
